메뉴 건너뛰기
The Lancet Neurology
Volumn 8, Issue 12, 2009, Pages 1085-1086
Do interferon beta-1b and glatiramer acetate grow brain?
Author keywords

[No Author keywords available]
Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;
EID: 71849109068     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70312-6     Document Type: Letter
Times cited : (2)
References (6)
  • 1
    • 69949098534 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    • O'Connor P., Filippi M., Arnason B., et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8 (2009) 889-897
    • (2009) Lancet Neurol , vol.8 , pp. 889-897
    • O'Connor, P.1    Filippi, M.2    Arnason, B.3
  • 2
    • 0027521002 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI results of a multicenter, randomized, double-blind, placebo-controlled trial
    • Paty D., and Li D. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 662-667
    • (1993) Neurology , vol.43 , pp. 662-667
    • Paty, D.1    Li, D.2
  • 3
    • 0032864616 scopus 로고    scopus 로고
    • Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis
    • Li D.K., and Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 46 (1999) 197-206
    • (1999) Ann Neurol , vol.46 , pp. 197-206
    • Li, D.K.1    Paty, D.W.2
  • 4
    • 34548635873 scopus 로고    scopus 로고
    • Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results
    • Barkhof F., Polman C.H., Radue E.W., et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 64 (2007) 1292-1298
    • (2007) Arch Neurol , vol.64 , pp. 1292-1298
    • Barkhof, F.1    Polman, C.H.2    Radue, E.W.3
  • 5
    • 54949143968 scopus 로고    scopus 로고
    • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
    • Coles A.J., Compston D.A., Selmaj K.W., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359 (2008) 1786-1801
    • (2008) N Engl J Med , vol.359 , pp. 1786-1801
    • Coles, A.J.1    Compston, D.A.2    Selmaj, K.W.3
  • 6
    • 34247513840 scopus 로고    scopus 로고
    • MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
    • Miller D.H., Soon D., Fernando K.T., et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68 (2007) 1390-1401
    • (2007) Neurology , vol.68 , pp. 1390-1401
    • Miller, D.H.1    Soon, D.2    Fernando, K.T.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.